These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 8995557

  • 41. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M, Miyazaki K.
    Clin Cancer Res; 2008 May 15; 14(10):3149-55. PubMed ID: 18483383
    [Abstract] [Full Text] [Related]

  • 42. Taxol: initial Israeli experience with a novel anticancer agent.
    Sulkes A, Beller U, Peretz T, Shacter J, Hornreich G, McDaniel C, Winograd B.
    Isr J Med Sci; 1994 Jan 15; 30(1):70-8. PubMed ID: 7908013
    [Abstract] [Full Text] [Related]

  • 43. [Paclitaxel (Taxol)--drug of choice in ovarian cancer].
    Fishman A.
    Harefuah; 1996 Apr 15; 130(8):557-60. PubMed ID: 8765885
    [No Abstract] [Full Text] [Related]

  • 44. [Favorable results of paclitaxel (Taxol) in patients with ovary carcinoma pretreated with platinum].
    Hoekman K, Huijskes RV, Burger CW, Verheijen RH, Pinedo HM, Vermorken JB.
    Ned Tijdschr Geneeskd; 1995 Feb 11; 139(6):272-8. PubMed ID: 7862216
    [Abstract] [Full Text] [Related]

  • 45. Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy--experience in an Asian population.
    Tay SK, Thilagam MD.
    Ann Acad Med Singap; 1998 Sep 11; 27(5):645-9. PubMed ID: 9919333
    [Abstract] [Full Text] [Related]

  • 46. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ.
    J Clin Oncol; 1994 Sep 11; 12(9):1748-53. PubMed ID: 7916038
    [Abstract] [Full Text] [Related]

  • 47. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
    Miglietta L, Amoroso D, Bruzzone M, Granetto C, Catsafados E, Mammoliti S, Guarneri D, Pedulla F, Foglia G, Ragni N, Martini MC, Brema F, Addamo G, Moraglio L, Pastorino G, Boccardo F.
    Oncology; 1997 Sep 11; 54(2):102-7. PubMed ID: 9075779
    [Abstract] [Full Text] [Related]

  • 48. Taxol administration.
    Rutherford C.
    J Intraven Nurs; 1994 Sep 11; 17(3):139-43. PubMed ID: 7914922
    [Abstract] [Full Text] [Related]

  • 49. Taxol: an important new drug in the management of epithelial ovarian cancer.
    Markman M.
    Yale J Biol Med; 1991 Sep 11; 64(6):583-90. PubMed ID: 1687343
    [Abstract] [Full Text] [Related]

  • 50. Primary chemotherapy in epithelial ovarian cancer.
    Hurwitz HI, McGuire WP.
    Obstet Gynecol Clin North Am; 1994 Mar 11; 21(1):141-54. PubMed ID: 7912423
    [Abstract] [Full Text] [Related]

  • 51. Platinum - sensitive relapsed epithelial ovarian cancer: not all the patients benefit from reinduction with carboplatin and paclitaxel.
    Milović-Kovačević M, Stamatovic L, Popov I, Radošević-Jelić L, Kezic I.
    Med Sci Monit; 2010 Nov 11; 16(11):CR549-54. PubMed ID: 20980960
    [Abstract] [Full Text] [Related]

  • 52. Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma.
    McGuire WP.
    Gynecol Oncol; 1993 Oct 11; 51(1):78-85. PubMed ID: 7902314
    [Abstract] [Full Text] [Related]

  • 53. Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy.
    Blom R, Palm N, Simonsen E.
    Acta Oncol; 1996 Oct 11; 35(6):733-6. PubMed ID: 8938222
    [Abstract] [Full Text] [Related]

  • 54. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
    Slichenmyer WJ, Donehower RC, Chen TL, Bowling MK, McGuire WP, Rowinsky EK.
    Cancer Chemother Pharmacol; 1995 Oct 11; 36(3):227-32. PubMed ID: 7781143
    [Abstract] [Full Text] [Related]

  • 55. Treatment of ovarian cancer: current status.
    Ozols RF.
    Semin Oncol; 1994 Apr 11; 21(2 Suppl 2):1-9; quiz 10, 58. PubMed ID: 7911254
    [Abstract] [Full Text] [Related]

  • 56. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Rose PG, Blessing JA, Mayer AR, Homesley HD.
    J Clin Oncol; 1998 Feb 11; 16(2):405-10. PubMed ID: 9469322
    [Abstract] [Full Text] [Related]

  • 57. [Taxol--a new cytostatic drug for therapy of ovarian and breast cancer].
    Meden H, Rath W, Kuhn W.
    Geburtshilfe Frauenheilkd; 1994 Apr 11; 54(4):187-93. PubMed ID: 7912212
    [Abstract] [Full Text] [Related]

  • 58. Chemotherapy for advanced epithelial ovarian cancer.
    Ozols RF.
    Hematol Oncol Clin North Am; 1992 Aug 11; 6(4):879-94. PubMed ID: 1500391
    [Abstract] [Full Text] [Related]

  • 59. Options for primary chemotherapy of epithelial ovarian cancer: taxanes.
    Trimble EL, Arbuck SG, McGuire WP.
    Gynecol Oncol; 1994 Dec 11; 55(3 Pt 2):S114-21. PubMed ID: 7835794
    [Abstract] [Full Text] [Related]

  • 60. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol.
    Pearl ML, Yashar CM, Johnston CM, Reynolds RK, Roberts JA.
    Gynecol Oncol; 1994 Jun 11; 53(3):339-43. PubMed ID: 7911444
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.